• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!

作者信息

Debbi Kamel, Loganadane Gokoulakrichenane, Roulin Louise, Belhadj Karim, Boukhobza Chahrazed, Saoudi Amira, Grellier Noémie, Belkacemi Yazid

机构信息

AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC), Paris, France.

Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, i-Biot, UPEC, Créteil, France.

出版信息

Rep Pract Oncol Radiother. 2024 Jul 22;29(3):409-411. doi: 10.5603/rpor.100780. eCollection 2024.

DOI:10.5603/rpor.100780
PMID:39144268
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11321792/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3591/11321792/bc43125596f2/rpor-29-3-409f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3591/11321792/c067e30dfb50/rpor-29-3-409f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3591/11321792/bc43125596f2/rpor-29-3-409f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3591/11321792/c067e30dfb50/rpor-29-3-409f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3591/11321792/bc43125596f2/rpor-29-3-409f2.jpg

相似文献

1
Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!达雷妥尤单抗-泊马度胺联合超分割全乳照射是安全的！
Rep Pract Oncol Radiother. 2024 Jul 22;29(3):409-411. doi: 10.5603/rpor.100780. eCollection 2024.
2
Pomalidomide combinations are a safe and effective option after daratumumab failure.泊马度胺联合方案是达雷妥尤单抗治疗失败后的安全有效选择。
J Cancer Res Clin Oncol. 2023 Aug;149(9):6569-6574. doi: 10.1007/s00432-023-04637-x. Epub 2023 Feb 13.
3
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤（APOLLO）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.
4
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.达雷妥尤单抗单药治疗与泊马度胺联合低剂量地塞米松治疗多发性骨髓瘤的疗效比较：匹配调整间接比较。
Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30.
5
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.皮下注射达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（APOLLO）：一项开放标签、随机、多中心、3 期临床试验的随访扩展。
Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1.
6
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.泊马度胺、地塞米松和达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者的免疫调节作用。
Clin Cancer Res. 2020 Nov 15;26(22):5895-5902. doi: 10.1158/1078-0432.CCR-20-1781. Epub 2020 Sep 14.
7
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.达雷妥尤单抗治疗后复发多发性骨髓瘤中基于卡非佐米/泊马度胺方案的疗效：加拿大骨髓瘤研究组数据库分析
Eur J Haematol. 2023 Nov;111(5):815-823. doi: 10.1111/ejh.14082. Epub 2023 Aug 13.
8
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.达雷妥尤单抗、泊马度胺和地塞米松联合疗法治疗对达雷妥尤单抗和/或泊马度胺难治的多发性骨髓瘤
Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11.
9
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.达雷妥尤单抗-来那度胺和达雷妥尤单抗-泊马度胺在复发性来那度胺暴露或难治性多发性骨髓瘤中的应用。
Anticancer Drugs. 2024 Jan 1;35(1):63-69. doi: 10.1097/CAD.0000000000001520. Epub 2023 Apr 6.
10
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.来那度胺治疗后复发或难治性多发性骨髓瘤日本患者的泊马度胺、地塞米松和达雷妥尤单抗。
Int J Hematol. 2022 Jul;116(1):122-130. doi: 10.1007/s12185-022-03338-4. Epub 2022 Apr 16.

本文引用的文献

1
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.达雷妥尤单抗治疗免疫球蛋白轻链淀粉样变性。
N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.
2
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.每周 1 周与 3 周（FAST-Forward）的分割式乳房放射治疗：来自多中心、非劣效性、随机、3 期试验的 5 年疗效和晚期正常组织效应结果。
Lancet. 2020 May 23;395(10237):1613-1626. doi: 10.1016/S0140-6736(20)30932-6. Epub 2020 Apr 28.
3
Daratumumab in multiple myeloma.
达雷妥尤单抗在多发性骨髓瘤中的应用。
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
4
The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era.现代多发性骨髓瘤联合治疗的安全性概况
Adv Radiat Oncol. 2018 Sep 27;4(1):112-117. doi: 10.1016/j.adro.2018.09.009. eCollection 2019 Jan-Mar.
5
Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab.使用鞘内化疗、放疗和达雷妥尤单抗治疗复发性中枢神经系统浆细胞瘤的持久治疗反应
Clin Case Rep. 2018 Mar 2;6(4):723-728. doi: 10.1002/ccr3.1451. eCollection 2018 Apr.
6
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.与英国FAST-Forward试验中采用的标准3周方案相比，全乳放疗1周方案相关的急性皮肤毒性。
Radiother Oncol. 2016 Jul;120(1):114-8. doi: 10.1016/j.radonc.2016.02.027. Epub 2016 Apr 1.
7
Pomalidomide.泊马度胺
Recent Results Cancer Res. 2014;201:359-72. doi: 10.1007/978-3-642-54490-3_22.